CSIMarket
 
Hologic Inc  (NASDAQ: HOLX)
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

Hologic Inc's Customers Performance

HOLX



 
HOLX's Source of Revenues During the corresponding time, Hologic Inc recorded a revenue increase by 44.84 % year on year, sequentially revenue fell by -46.45 %. While revenue at the Hologic Inc's corporate clients

List of HOLX Customers




for the same period Hologic Inc recorded revenue increase by 44.84 % year on year, sequentially revenue fell by -46.45 %.

List of HOLX Customers

Hologic Inc's Business Units
United States    0 % of total Revenue
International    30.23 % of total Revenue
Diagnostics    51.18 % of total Revenue
Diagnostics United States    37.44 % of total Revenue
Diagnostics International    13.74 % of total Revenue
Diagnostics Cytology Perinatal    13.97 % of total Revenue
Diagnostics Cytology Perinatal United States    8.38 % of total Revenue
Diagnostics Cytology Perinatal International    5.6 % of total Revenue
Diagnostics Molecular Diagnostics    36.28 % of total Revenue
Diagnostics Molecular Diagnostics United States    28.14 % of total Revenue
Diagnostics Molecular Diagnostics International    8.14 % of total Revenue
Diagnostics Blood Screening    0.93 % of total Revenue
Diagnostics Blood Screening United States    0.93 % of total Revenue
Breast Health    41.43 % of total Revenue
Breast Health United States    32.08 % of total Revenue
Breast Health International    9.35 % of total Revenue
Breast Health Breast Imaging    30.86 % of total Revenue
Breast Health Breast Imaging United States    24.23 % of total Revenue
Breast Health Breast Imaging International    6.62 % of total Revenue
Breast Health Interventional Breast Solutions    10.57 % of total Revenue
Breast Health Interventional Breast Solutions United States    7.85 % of total Revenue
Breast Health Interventional Breast Solutions International    2.72 % of total Revenue
GYN Surgical    19.93 % of total Revenue
GYN Surgical United States    14.21 % of total Revenue
GYN Surgical International    5.72 % of total Revenue
Skeletal Health    2.94 % of total Revenue
Skeletal Health United States    1.52 % of total Revenue
Skeletal Health International    1.42 % of total Revenue
Europe    0 % of total Revenue
Asia-Pacific    0 % of total Revenue
Rest of World    0 % of total Revenue
Disposables    70.99 % of total Revenue
Capital equipment components and software    20.63 % of total Revenue
Service    23.25 % of total Revenue
Other    0.6 % of total Revenue






Hologic Inc's Comment on Sales, Marketing and Customers



Hologic provides automated systems for consolidating lab developed tests (LDTs) and in vitro diagnostic (IVD) assays. Its Breast Health segment serves the breast imaging, biopsy, breast surgery, and pathology markets with products including 3D digital mammography systems, AI-based image analysis software, biopsy guidance systems, and specimen radiology systems. Key breast imaging platforms include Selenia Dimensions and 3Dimensions. The GYN Surgical segment offers products for hysteroscopic tissue removal, endometrial ablation, fluid management, transcervical and laparoscopic radiofrequency ablation, vessel sealing, and surgical stapling. Devices in this segment include MyoSure, NovaSure, Fluent, Sonata, Acessa ProVu, CoolSeal, and the JustRight stapler. The Skeletal Health segment provides bone density and body composition assessment systems, such as Horizon DXA, and orthopedic surgical imaging with the Fluoroscan Insight FD mini C-arm. Sales of the Fluoroscan Insight FD are scheduled to discontinue in fiscal 2026.





Hologic Inc’s Comment on Sales, Marketing and Customers


Hologic provides automated systems for consolidating lab developed tests (LDTs) and in vitro diagnostic (IVD) assays. Its Breast Health segment serves the breast imaging, biopsy, breast surgery, and pathology markets with products including 3D digital mammography systems, AI-based image analysis software, biopsy guidance systems, and specimen radiology systems. Key breast imaging platforms include Selenia Dimensions and 3Dimensions. The GYN Surgical segment offers products for hysteroscopic tissue removal, endometrial ablation, fluid management, transcervical and laparoscopic radiofrequency ablation, vessel sealing, and surgical stapling. Devices in this segment include MyoSure, NovaSure, Fluent, Sonata, Acessa ProVu, CoolSeal, and the JustRight stapler. The Skeletal Health segment provides bone density and body composition assessment systems, such as Horizon DXA, and orthopedic surgical imaging with the Fluoroscan Insight FD mini C-arm. Sales of the Fluoroscan Insight FD are scheduled to discontinue in fiscal 2026.








HOLX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Hologic Inc 17,087.75 3,644.80 543.80 7,070
SUBTOTAL 0.00 0.00 0.00 -

Sources: Hologic Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Hologic Inc’s corporate clients.
For your research, we’ve provided 9 tables on Hologic Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.